Great ariticle, would you like_老虎社区_美港股上老虎

2020-11-22

Great ariticle, would you like to share it?

Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":399152806,"tweetId":"399152806","gmtCreate":1606044855605,"gmtModify":1703840729042,"author":{"id":3568479083861646,"idStr":"3568479083861646","authorId":3568479083861646,"authorIdStr":"3568479083861646","name":"titeufakina","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","htmlText":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","text":"Great ariticle, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/399152806","repostId":2084281420,"repostType":4,"repost":{"id":"2084281420","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1062363208","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1605860434,"share":"https://www.laohu8.com/m/news/2084281420?lang=&edition=full","pubTime":"2020-11-20 16:20","market":"other","language":"en","title":"Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2084281420","media":"Reuters","summary":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 mil","content":"<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast    that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis signs $50 mln deal for Mesoblast cell therapy for COVID, beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1062363208\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2020-11-20 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast    that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.</p><p>The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome <a href=\"https://laohu8.com/S/ARDS\">$(ARDS)$</a>, including that associated with COVID-19, for which the therapy is currently in late-stage trials.</p><p>While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.</p><p>\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.</p><p>Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSB.AU":"MESOBLAST LTD","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2084281420","content_text":"ZURICH, Nov 20 (Reuters) - Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast    that it hopes to deploy for COVID-19 patients as well as others suffering from respiratory distress.The Swiss drugmaker's deal with Australia-based Mesoblast secures rights to develop, commercialize and manufacture Remestemcel-L for treating acute respiratory distress syndrome $(ARDS)$, including that associated with COVID-19, for which the therapy is currently in late-stage trials.While the therapy has shown promise in COVID-19 patients -- -- in a compassionate use programme in March in 12 patients, Remestemcel-L was associated with an 83% survival rate -- Novartis wants the medicine for beyond the pandemic, too, to help patients who in normal times also land in the hospital with ARDS and often die.\"It has the potential to be the first treatment for the most critically ill ARDS patients, and it provides us with an opportunity to apply years of specialized experience directly to the work of saving lives,\" Novartis's chief drug developer, John Tsai, said on Friday.Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":602,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/399152806"}